Core Insights - The reactivation of the fifth listing standard on the Sci-Tech Innovation Board (STAR Market) aims to support high-growth technology companies, particularly in the biopharmaceutical sector, by allowing companies without profits to list based on expected market capitalization and R&D achievements [1][19] - The biopharmaceutical industry, especially innovative drug companies, faces longer investment periods and higher uncertainty due to strict regulatory requirements for product approval, making them highly reliant on capital [1][19] - Since the reactivation in June 2025, companies like He Yuan Bio and Bei Xin Life have made significant progress, signaling a positive outlook for other biopharmaceutical firms still in clinical stages [2] Market Performance - The innovative drug sector has seen a remarkable stock performance in 2025, driven by favorable policy changes, relaxed procurement policies, and the growth of commercial health insurance, which enhances market expectations for innovative drugs [3] - The 20 companies that successfully listed under the fifth standard have achieved a total market capitalization of 364.12 billion, with an average increase of 79.10% since the beginning of 2025 [3][7] Financial Performance - In 2024, the 20 companies reported a combined revenue exceeding 14.3 billion, a year-on-year growth of 45%, with 16 companies generating over 1 billion in revenue [12][16] - The total R&D expenses for these companies accounted for 67% of their total revenue, indicating a high dependency on external financing for continued innovation [16][18] R&D and Innovation - The 20 companies listed under the fifth standard have collectively developed 45 drug varieties, with 22 classified as first-class new drugs or innovative biological products, covering various advanced therapeutic areas [8][10] - The number of candidate products in the R&D pipeline for these companies has exceeded 200, showcasing their commitment to innovation and market expansion [8] Regulatory Environment - The reactivation of the fifth standard reflects a shift in regulatory focus towards recognizing the inherent risks and long timelines associated with technology innovation, moving away from traditional financial metrics [19][20] - The introduction of a "Sci-Tech Growth Tier" aims to enhance information disclosure and regulatory oversight for companies listed under the fifth standard, ensuring a balance between support and supervision [22]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.3810 yuan, reflecting a decline of 1.11% [1] - The fund has achieved a return of 12.70% over the past month, ranking 117 out of 717 in its category; a return of 29.84% over the past six months, ranking 54 out of 704; and a year-to-date return of 28.51%, ranking 62 out of 702 [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xin Li Tai (6.70%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan, managed by fund manager Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having worked in various roles since joining ICBC Credit Suisse in 2010 [2]

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 閣下如對本通函任何內容或將採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證券交易商、銀行經理、 律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有的榮昌生物製藥（煙台）股份有限公司股份，應立即將本通函連同隨附代表委任表格送交 買主或承讓人或經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） (1)建議修訂《公司章程》 (2)建議修訂股東會議事規則 及 2025年第二次H股類別股東大會通告 榮昌生物製藥（煙台）股份有限公司謹訂於2025年7月31日下午二時正假座中國山東省自由貿易試驗區煙台片區煙台 開發區北京中路58號公司三期大樓6134會議室召開H股類別股東大會，大會通告載列於本通函內。本 ...

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Group 1: Core Insights - A-share companies are experiencing significant overseas expansion, with notable achievements in infrastructure, biomedicine, and equipment manufacturing, leading to large overseas orders [2][3] - The shift in Chinese enterprises' overseas strategy is moving from cost-driven to innovation-driven, leveraging advanced supply chains, international talent, and digital technologies [2] Group 2: Large Orders and Competitive Strength - A-share companies have secured substantial overseas contracts, particularly in the infrastructure sector, with notable projects including a $1.6 billion contract for a gas processing plant in Iraq and contracts totaling approximately 5.34 billion yuan for the China-Kyrgyzstan-Uzbekistan railway [3][4] - In the biomedicine sector, companies like Rongchang Bio are accelerating internationalization, exemplified by a licensing agreement with Vor Bio worth up to $4.1 billion [4] - Equipment manufacturing firms are also making strides, with agreements such as a $406 million contract for a conveyor system in Guinea, enhancing their international market presence [4] Group 3: Accelerated Overseas Capacity Layout - Several A-share companies are intensifying their overseas production capacity, viewing local production as a key driver for global competitiveness [6] - Companies like Linglong Tire are investing $1.193 billion in a production base in Brazil, aiming for an annual output of 14.7 million high-performance tires [6] - Other firms, such as North Special Technology and Zhongke Electric, are also establishing production bases in Thailand and Oman, respectively, to enhance their global supply chain [7] Group 4: Rising Trend of Overseas Mergers and Acquisitions - The number of disclosed overseas mergers and acquisitions by A-share companies has surpassed 60 in the first half of the year, with a focus on electronics, automotive parts, and machinery [9] - Companies are pursuing overseas acquisitions to enter emerging markets and enhance their technological capabilities, as seen with Dongshan Precision's dual acquisitions in the optical communication sector [9][10] - The strategy of overseas mergers and acquisitions is aimed at resource and market integration, with firms like Luoyang Molybdenum consolidating their overseas mineral resource reserves [10]

Market Overview - The Sci-Tech Innovation Board (科创板) index fell by 0.89%, closing at 983.11 points, with a total trading volume of 2.85 billion shares and a turnover of 94.90 billion yuan, resulting in a weighted average turnover rate of 1.59% [1] - Among the tradable stocks on the Sci-Tech Innovation Board, 180 stocks closed higher, with 5 stocks rising over 10%, including Aowei New Materials, Haosen Intelligent, and Qinchuan Internet of Things, which hit the daily limit [1] Trading Activity - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 11 stocks had rates between 10% and 20%, and 36 stocks had rates between 5% and 10% [1] - C Yitang, a newly listed stock, had the highest turnover rate at 50.54%, closing down by 9.66% with a trading volume of 2.20 billion yuan and a net outflow of 134 million yuan [1][2] - Other notable stocks with high turnover rates include Jinchengzi, which closed down by 5.60% with a turnover rate of 25.85%, and Xinyuren, Sikan Technology, and Meidixi, with turnover rates of 18.75%, 16.84%, and 16.24% respectively [1][2] Sector Performance - In the high turnover rate stocks, the pharmaceutical and biological sector had the most representation, with 10 stocks listed, followed by the power equipment and machinery sectors, each with 8 stocks [2] - Among the high turnover stocks, 23 stocks saw an increase, with Haosen Intelligent, Qinchuan Internet of Things, and Meidixi leading with gains of 20.02%, 19.98%, and 13.36% respectively [2] Fund Flow - In terms of fund flow, 22 stocks experienced net inflows, with the highest inflows seen in Huyou Pharmaceutical, Jinchengzi, and Jiayuan Technology, with net inflows of 59.84 million yuan, 40.28 million yuan, and 38.97 million yuan respectively [2] - Conversely, C Yitang, Zhengfan Technology, and Weice Technology had the largest net outflows, with outflows of 134 million yuan, 62.06 million yuan, and 61.24 million yuan respectively [2] Leverage Fund Movements - Recent data indicates that 28 stocks have received net purchases from leveraged funds, with C Yitang, Huyou Pharmaceutical, and Rongchang Bio having the largest increases in financing balances of 208 million yuan, 114 million yuan, and 6.05 million yuan respectively [3]

Group 1 - As of the end of Q2 2025, the total market value of northbound funds reached 2.29 trillion yuan, an increase of over 2% compared to the end of Q1, with the number of shares held reaching 123.51 billion, a growth of over 3% [1] - Northbound funds showed a significant structural adjustment in industry allocation, with over 20 industries seeing an increase in holdings, accounting for more than 60% of the 31 industries tracked [3] - The social services industry has been continuously favored by northbound funds for three consecutive quarters, indicating sustained foreign interest in this sector [3] Group 2 - The retail trade industry saw the most significant increase, with a 28.69% rise in the number of shares held and a market value increase of over 45%, reaching 19.75 billion yuan [3] - The defense and military industry also received notable attention, with a 12.5% increase in holdings, and its index leading the market with over a 15% rise in Q2 [3] - In contrast, the oil and petrochemical, textile and apparel, electronics, and home appliances industries experienced a decline in holdings of over 10% [3] Group 3 - Over 1,500 individual stocks saw an increase in holdings by northbound funds, reflecting a clear value orientation [4] - The top ten stocks held by northbound funds include Ningde Times, Kweichow Moutai, and Midea Group, with holdings in Ningde Times exceeding 150 billion yuan and Kweichow Moutai over 100 billion yuan [4] - Notable increases in holdings were observed in Huaming Equipment, Rongchang Biology, and Huayou Cobalt, with Huaming Equipment's latest holding ratio at 17.45%, reflecting a more than 6 percentage point increase [4]

Core Viewpoint - Chinese innovative pharmaceuticals are accelerating their international expansion, with significant licensing deals and supportive policies facilitating this trend [2][6][7]. Group 1: Market Activity - In the first half of the year, the upfront payments for innovative drug licensing exceeded $2.5 billion, with total transaction amounts nearing $50 billion, almost matching the total for the previous year [2]. - A notable licensing agreement was signed between 3SBio and Pfizer, valued at up to $60.5 billion, involving the exclusive rights for the PD-1/VEGF bispecific antibody SSGJ-707 outside of mainland China [3]. - Rongchang Bio announced a licensing deal with Vor Biopharma Inc. with a total transaction value of $4.23 billion, including an upfront payment of $45 million [3]. Group 2: Policy Support - The rapid development of the innovative drug industry is supported by policy reforms, including expedited drug review processes and dynamic adjustments to the medical insurance catalog [6][7]. - In the first half of the year, 43 innovative drugs and 45 innovative medical devices were approved, representing year-on-year increases of 59% and 87%, respectively [6]. - Recent measures have been introduced to support the internationalization of innovative drugs, encouraging companies to explore markets in Southeast Asia and Central Asia [7]. Group 3: Industry Trends - The internationalization strategies of Chinese pharmaceutical companies are diversifying, with four main models identified: independent internationalization, licensing, NewCo model, and mergers and acquisitions [5]. - The collaboration landscape is broadening, with partnerships not only with traditional pharmaceutical companies but also with emerging biotech firms [4]. - Despite the progress, challenges remain, including weaknesses in basic research, target homogeneity, regulatory alignment, and commercialization capabilities [7].

Group 1 - The Hong Kong stock market's innovative drug sector continues to strengthen, with Rongchang Biologics rising over 7% [1] - Junshi Biosciences increased by more than 4% [1] - Tigermed (300347) and Zhaoyan New Drug (603127) both saw gains of over 3% [1] Group 2 - Innovent Biologics and Kanglong Chemical (300759) experienced increases of over 2% [1]

Group 1 - The China Securities Innovation Drug Industry Index (931152) increased by 0.55%, with notable stock performances including Zhenhua Cell (688520) up 16.46%, Rongchang Bio (688331) up 10.65%, and Aosaikang (002755) up 10.00% [1] - The Innovation Drug 50 ETF (159835) has shown a cumulative increase of 33.49% over the past year, indicating significant growth in its market share [1] - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, marking a pivotal step in the integration of commercial health insurance into the multi-tiered medical security system [1] Group 2 - Multiple policy releases are seen as significant for the development of innovative drugs, with the introduction of a commercial health insurance innovative drug directory expected to expand market opportunities and encourage pharmaceutical companies to enhance R&D efforts [2] - The domestic innovative drug industry is anticipated to reach a turning point by 2025, shifting from capital-driven growth to profit-driven growth, presenting dual opportunities for performance and valuation recovery [2] - The Innovation Drug 50 ETF closely tracks the China Securities Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug R&D to reflect the overall performance of the innovative drug sector [2]